John Parkinson

The Outpatient Automated Stewardship Information System (OASIS) is a platform that allows clinicians the ability to improve their prescribing practices in hopes of delivering a more judicious approach and moving towards stewardship.

The federal agency has identified a total of 5 cases in Florida and Texas within the last two months.

As this annual day of recognition gets underway, free testing can be found throughout the United States.

The strain, identified as EU11, accounts for 1.7% of cases nationwide in the United States.

The film is part of a GSK campaign, Ask2BSure, that addresses this issue.

The vaccine manufacturer has incorporated spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for its mRNA-1273.815 COVID-19 vaccine.

The CDC reports that during 2020-2021, the mortality rates for COVID-19—associated fungal Infections were significantly higher than non-COVID-19–associated fungal infections.

Biopharmaceutical company, Vaccitech, has developed its VTP-300 vaccine, and is presenting a poster demonstrating positive early data at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.

A company has developed an intelligence platform for better understanding influenza and other viral trends.

In a large observational study, significant information was obtained about protection against acute infection and disease severity in this age group.

The agency said that in recent days a few more suppliers initiated a voluntary recall of additional select packages sold at national stores.

The federal agency explains this increase in 2022 was substantial compared to previous years, and recommends this population be up-to-date on vaccines for it.

The first patient was dosed for this open-label trial.

The American College of Physicians (ACP) CEO says it is important for physicians to move away from this traditional approach to transition to an empathetic style of discussion with patients so they can better relate and help those in need get back on track with their health post-COVID and schedule routine tests and immunizations.

With an estimated 30% of Americans living with a tattoo, the federal agency has developed guidance designed to give manufacturers information and resources to prevent potential health issues.

Metformin was shown to decrease the condition by 41%; whereas, ivermectin and fluvoxamine treatment did not see a clinical benefit.

A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.

The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.

The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.

The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.

A new documentary looks at dealing with the condition long-term, and serves as a microcosm for how people suffer through chronic conditions and diseases, and may not get the help they need.

Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

A clinician talks about reducing antibiotic treatment duration for urinary tract infections (UTI).

A large study of patients treated in the intensive care unit (ICU) demonstrates common genetic links that point to a potential reason for people progressing to life-threatening forms of the respiratory virus.

An antibiotic development stakeholder believes the current paradigm needs to be changed in order for more antibiotics to get FDA approved and reduce multidrug-resistance.

This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.